ChipMOS TECHNOLOGIES (NASDAQ:IMOS) reported quarterly earnings of $0.14 per share. This is a 90.07 percent decrease over earnings of $1.41 per share from the same period last year. The company reported $152.50 million in sales this quarter. This is a 37.70 percent decrease over sales of $244.80 million the same period last year.
Protagonist Therapeutics Announces Data From Phase 2 Rusfertide Study In Hereditary Hemochromatosis Selected For Oral Presentation At The Annual AASLD Meeting
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase 2 study of rusfertide in hereditary
